Clinical trials are more complex than ever, yet one of the most overlooked risks to successful execution is workforce continuity. While sponsors routinely assess risks related to recruitment, protocol complexity, and investigator performance, the impact of team turnover is often underestimated.
Workforce continuity is more than an HR metric – it is a critical operational risk-control mechanism that directly affects study quality, execution, speed, protocol compliance, site engagement, and sponsor value.
Continuity challenges are not limited to employee attrition. In many cases, study disruption occurs when experienced team members transition to other projects. Even when expertise remains within the organization, changes in key study personnel can require significant knowledge transfer and relationship rebuilding.
At Linical, an industry-leading 85% employee retention rate and average tenure of seven years help ensure consistency throughout the clinical trial lifecycle. Fostering a stable, engaged, and experienced workforce ensures consistent delivery, strong sponsor partnerships, and measurable financial value.
Workforce turnover is an underestimated source of clinical trial execution risk. Every staff transition introduces a knowledge transfer event. These transitions are rarely budgeted separately, yet they consume sponsor, site, and CRO resources. Protocol familiarization, onboarding, and relationship rebuilding all require time and can introduce variability into study execution.
In complex studies, repeated handovers can affect site relationships, monitoring consistency, issue resolution timelines, and overall study efficiency. While sponsors routinely assess risks associated with recruitment, protocol complexity and investigator performance, workforce continuity is seldom evaluated with the same rigor despite its direct impact on trial execution.
Linical prioritizes retention of well-qualified, experienced staff, setting itself apart with above-industry retention rates allowing teams to remain consistent from study start to close-out.
A stable workforce enables:
At Linical, continuity is not just an HR metric. This is a strategic advantage embedded into how trials are executed globally.
As Alison Messom, PhD, Executive Vice President Global Operations explains: “Our people are one of Linical’s greatest strengths. The longevity of our teams allows us to deliver consistency and deep therapeutic expertise that sponsors can rely on throughout the life of a program.”
This continuity translates directly into improved quality outcomes:
When teams remain engaged throughout the lifecycle of a trial, they build institutional knowledge that minimizes errors and enhances compliance—critical factors in today’s highly regulated environment.
Trust and collaboration are foundational to clinical research success. Workforce continuity fosters relationships that go beyond transactional interactions, including:
With Sponsors
With Investigative Sites
Linical emphasizes relationship continuity as a key differentiator, recognizing that strong partnerships drive smoother trial execution and better outcomes.
Workforce stability is also a reflection of a healthy organizational culture. High retention signals:
Engaged employees are more likely to demonstrate:
This positive culture creates a virtuous cycle—motivated teams deliver better results, which in turn strengthens retention.
Reduced Operational Costs
Better Budget Predictability
Ultimately, workforce continuity supports on-time, on-budget delivery, a key metric for sponsors evaluating CRO performance.
In an industry that continues to experience workforce volatility, sponsors increasingly recognize the value of partnering with organizations that provide continuity across every stage of study execution. At Linical, this is achieved through:
These elements enable Linical to maintain consistent, high-performing teams that deliver across therapeutic areas and geographies.
Most CRO evaluations focus on who wins the work. Sponsors should also consider who is likely to still be delivering the work three years later.
At Linical, we recognize that people are at the heart of clinical research.
Contact our team to explore a partnership built on continuity and performance.
Author:
Suzanne Mathias
Senior Director, Clinical Monitoring